2021 Revenues ($USD) : $3,206,900,947
2021 Revenues (foreign currencies) : JP¥352,246,000,000
2021 R&D spend : $525,118,354
2021 Number of Employees : 5,752
Fiscal Year End : 12/31/2021
Leader : CEO Masashi Miyamoto

The Tokyo-headquartered pharmaceutical and biotechnology firm focuses on developing drugs in oncology, nephrology, central nervous system and immunology. Focus areas for its drug discovery efforts include therapeutic antibodies, small molecule drugs, nucleic acid drugs and regenerative medicine. Central products include anemia treatments ESPO and Nesp — as well as G-Lasta, a sustained duration form of granulocyte colony-stimulating factor product of chemotherapy-induced neutropenia. —BB